Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman’s disease who received siltuximab (Sylvant).

Interleukin-6 (IL-6) plays a pivotal role in both multicentric Castleman’s disease and cachexia (loss of weight, muscle atrophy, fatigue, weakness). In this study, the mean maximal gain in LBM in the siltuximab-treated patients was 2.4 kg compared with 1.1 kg in those receiving placebo.

Further, Sawyer says, greater than 50% of patients treated with siltuximab gained more than 1 kg of LBM at first CT exam at 9 weeks. At no point did patients receiving placebo reach that level.

Videos

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).


Michael Sawyer, MD

Articles

Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease